Medscape5d
FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Medindia2d
FDA Approves Esketamine Nasal Spray for Resistant Depression
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Medical News Today3d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Verywell Health on MSN1d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
WebMD2d
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The American Journal of Managed Care8d
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
Hosted on MSN8d
FDA Expands Approval of Esketamine for Depression
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
Daily7d
FDA Approves Esketamine Nasal Spray for Treatment-Resistant Depression
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...